Option Care Health, Inc. $OPCH Shares Sold by American Century Companies Inc.

Key Points

• American Century Companies Inc. has significantly reduced its stake in Option Care Health, Inc., selling 1,223,779 shares, which represents a 96.1% decrease in ownership during the first quarter.
• Additionally, notable institutional investments include Northern Trust Corp increasing its stake by 11.8% and Allspring Global Investments increasing its holdings by a staggering 6,525,926.1%.
• Analyst reports reflect a generally positive outlook for Option Care Health with a consensus rating of "Moderate Buy" and an average price target of $35.75, following the company’s recent earnings beat.

American Century Companies Inc. trimmed its holdings in Option Care Health, Inc. (NASDAQ:OPCH - Free Report) by 96.1% during the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 49,744 shares of the company's stock after selling 1,223,779 shares during the quarter. American Century Companies Inc.'s holdings in Option Care Health were worth $1,739,000 at the end of the most recent reporting period.

Several other hedge funds have also modified their holdings of OPCH. Bessemer Group Inc. lifted its stake in Option Care Health by 62.3% in the 1st quarter. Bessemer Group Inc. now owns 1,560 shares of the company's stock valued at $54,000 after buying an additional 599 shares in the last quarter. Public Employees Retirement System of Ohio boosted its position in shares of Option Care Health by 21.6% during the 4th quarter. Public Employees Retirement System of Ohio now owns 1,870 shares of the company's stock worth $43,000 after purchasing an additional 332 shares during the period. Wealthquest Corp purchased a new position in shares of Option Care Health during the 1st quarter worth approximately $66,000. Farther Finance Advisors LLC boosted its position in shares of Option Care Health by 434.8% during the 1st quarter. Farther Finance Advisors LLC now owns 1,920 shares of the company's stock worth $67,000 after purchasing an additional 1,561 shares during the period. Finally, UMB Bank n.a. boosted its position in shares of Option Care Health by 82.7% during the 1st quarter. UMB Bank n.a. now owns 2,149 shares of the company's stock worth $75,000 after purchasing an additional 973 shares during the period. 98.05% of the stock is owned by hedge funds and other institutional investors.

Option Care Health Stock Up 1.7%

NASDAQ:OPCH traded up $0.49 during midday trading on Wednesday, hitting $28.93. 1,900,211 shares of the company were exchanged, compared to its average volume of 1,717,588. The company has a fifty day simple moving average of $29.42 and a 200 day simple moving average of $31.59. Option Care Health, Inc. has a fifty-two week low of $21.39 and a fifty-two week high of $35.53. The company has a current ratio of 1.52, a quick ratio of 1.00 and a debt-to-equity ratio of 0.81. The company has a market capitalization of $4.70 billion, a PE ratio of 23.14, a price-to-earnings-growth ratio of 1.75 and a beta of 0.82.

Option Care Health (NASDAQ:OPCH - Get Free Report) last announced its quarterly earnings results on Wednesday, July 30th. The company reported $0.41 EPS for the quarter, topping the consensus estimate of $0.40 by $0.01. Option Care Health had a net margin of 3.93% and a return on equity of 17.53%. The firm had revenue of $1.42 billion for the quarter, compared to analyst estimates of $1.35 billion. During the same period last year, the business earned $0.30 EPS. Option Care Health's revenue for the quarter was up 15.4% compared to the same quarter last year. Option Care Health has set its FY 2025 guidance at 1.650-1.720 EPS. As a group, equities analysts anticipate that Option Care Health, Inc. will post 1.22 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on OPCH shares. Citigroup reaffirmed an "outperform" rating on shares of Option Care Health in a research report on Thursday, July 31st. Barrington Research reissued an "outperform" rating and issued a $38.00 price target on shares of Option Care Health in a research report on Thursday, July 10th. Finally, JMP Securities raised their price target on shares of Option Care Health from $36.00 to $38.00 and gave the company a "market outperform" rating in a research report on Thursday, July 31st. Eight equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company's stock. According to data from MarketBeat.com, Option Care Health has a consensus rating of "Moderate Buy" and an average price target of $35.75.

Insider Buying and Selling at Option Care Health

In other Option Care Health news, Director Harry M. Jansen Kraemer, Jr. acquired 36,000 shares of the company's stock in a transaction on Wednesday, August 20th. The shares were bought at an average cost of $27.15 per share, for a total transaction of $977,400.00. Following the completion of the purchase, the director owned 375,390 shares in the company, valued at $10,191,838.50. This trade represents a 10.61% increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Timothy P. Sullivan acquired 20,000 shares of the company's stock in a transaction on Thursday, August 21st. The stock was acquired at an average price of $27.51 per share, for a total transaction of $550,200.00. Following the completion of the purchase, the director owned 49,229 shares of the company's stock, valued at $1,354,289.79. This trade represents a 68.43% increase in their position. The disclosure for this purchase can be found here. 0.64% of the stock is owned by company insiders.

Option Care Health Company Profile

Option Care Health, Inc offers home and alternate site infusion services in the United States. The company provides anti-infective therapies; home infusion services to treat heart failures; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including crohn's disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders.